Welcome to our dedicated page for 23Andme Holding Co news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding Co stock.
News for 23andMe Holding Co. (Nasdaq: ME), now renamed Chrome Holding Co. in SEC filings, centers on its evolution as a genetics-led consumer healthcare, biotechnology, and research company and on significant corporate restructuring events. Press releases describe 23andMe as a human genetics company with a mission to help people access, understand, and benefit from the human genome, and as a genetics-led consumer healthcare and research or biopharmaceutical company empowering a healthier future.
Visitors to this news feed can review updates on Chapter 11 proceedings, including the company’s voluntary filing in the U.S. Bankruptcy Court for the Eastern District of Missouri, court approvals of first-day motions, and the launch of a court-supervised sale process. Releases detail the company’s efforts to obtain debtor-in-possession financing, sell substantially all of its assets, and address operational, financial, and legal challenges, as well as subsequent SEC reports on the approved and completed sale of assets to 23andMe Research Institute.
The news stream also covers strategic and operational developments such as the exploration of strategic alternatives, workforce reductions, discontinuation of the Therapeutics operating segment, and restructuring initiatives aimed at cost reductions. Financial results announcements provide context on revenue trends, changes in operating expenses, and management’s previously stated concerns about liquidity and ability to continue as a going concern before the Chapter 11 filing.
In addition, 23andMe’s news highlights product and research updates, including new genetic reports for 23andMe+ Premium members on topics such as osteoporosis and homocysteine (MTHFR-related) levels, the launch of Discover23 for biopharma collaborators, and collaborations with partners like Mirador Therapeutics. Telehealth and preventive health initiatives, such as GLP-1 weight loss offerings on the Lemonaid Health platform and a comprehensive longevity service, also appear in company communications.
For investors and observers following ME-related developments, this page aggregates company-issued news on genetics products, research collaborations, telehealth services, financial performance, governance changes, and the ongoing Chapter 11 restructuring and asset sale process.
23andMe (NASDAQ: ME) faced a significant data breach in December 2023, affecting approximately 7 million users. A recently filed class complaint alleges that hackers specifically targeted the personal genetic information of Jewish and Chinese customers. The breach resulted in the compilation and sale of sensitive data on the dark web, including genetic heritage, names, and addresses. Key points:
- Over 1 million Jewish customers' data was leaked in retaliation for the Israel-Hamas war
- 350,000 Chinese customers' data was leaked upon request
- 23andMe allegedly concealed these details when notifying affected customers
- The company attempted to shift blame to customers for using recycled login credentials
- A class action lawsuit is being pursued for affected customers, particularly those with Ashkenazi Jewish heritage or Chinese ancestry
23andMe (NASDAQ:ME) experienced a significant data breach in December 2023, affecting approximately 7 million users. A class action complaint reveals that hackers specifically targeted the personal genetic information of Jewish and Chinese customers. The breach resulted in the leak of over 1 million Jewish customers' data and 350,000 Chinese customers' information on the dark web. The lawsuit alleges that 23andMe concealed the targeted nature of the attack and has not informed affected customers about the extent of the data disclosure.
The hacker, using the alias "Golem," leaked the data on Breach Forums, pricing customer profiles from $1,000 for 100 profiles to $100,000 for 100,000 profiles. 23andMe initially attributed the breach to recycled login credentials and delayed reporting the full extent of the incident. Levi & Korsinsky, LLP is investigating potential compensation for affected customers, particularly those with Ashkenazi Jewish heritage or Chinese ancestry in specific states.
The Special Committee of 23andMe's Board of Directors has rejected CEO Anne Wojcicki's proposal to take the company private at $0.40 per share. The committee deemed the offer insufficient and not in the best interest of non-affiliated shareholders, citing lack of premium, committed financing, and its conditional nature. They requested Wojcicki to withdraw her intent to oppose alternative transactions and provided a two-week window for a revised, fully-financed proposal. The committee plans to engage a consultant to advise on a revised business plan for a more sustainable financial profile and path to profitability. Wells Fargo is serving as financial advisor, and Dechert LLP as legal advisor to the Special Committee.
23andMe Holding Co. (Nasdaq: ME) has received a take-private proposal from its CEO, Anne Wojcicki. The offer, announced on July 31, 2024, proposes to acquire all outstanding shares not owned by Wojcicki or her affiliates for $0.40 per share in cash. This applies to both Class A and Class B Common Stock. The company's Special Committee is carefully reviewing the proposal, with Wells Fargo as financial advisor and Dechert LLP as legal counsel. The committee emphasizes its commitment to acting in the best interests of 23andMe and its shareholders. However, there is no guarantee of any specific outcome from this proposal.
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has announced it will report its Q1 FY2025 financial results on Thursday, August 8, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the quarter's results and business progress.
Shareholders can access the webcast at https://investors.23andme.com/news-events/events-presentations. Additionally, 23andMe is using the Say Technologies platform to allow shareholders to submit and upvote questions for management before the earnings call. The Q&A platform will be open until 24 business hours before the call.
23andMe Holding Co. (Nasdaq: ME) and 20 lung cancer advocacy organizations have launched the Lung Cancer Genetics Study to advance research in lung cancer. The study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data to improve detection, risk reduction, and care. Key points:
- Goal: Recruit 10,000 people diagnosed with lung cancer
- Participants: U.S. residents, 18+ years old, diagnosed with lung cancer
- Data collected: Genetic information, self-reported experiences, medical records, tumor biomarker information
- Access: De-identified data available to approved researchers; free access for nonprofit researchers and institutions
The study is supported by Troper Wojcicki Philanthropies and aims to address the critical need for understanding lung cancer genetics and improving outcomes for future generations.
23andMe and Nightingale Health have announced a strategic collaboration to pilot Nightingale’s blood metabolomics panel with 23andMe members. The partnership aims to enhance preventive health measures by integrating blood testing with 23andMe’s genetic services. The pilot will offer up to 5,000 23andMe+ Premium and Total Health members free access to Nightingale’s Remote Health Check, which measures biomarkers related to disease risk. The initiative seeks to combine genetic data with blood biomarkers to improve health predictions and interventions. The collaboration underscores both companies' commitment to proactive health management.
On June 14, 2024, 23andMe (NASDAQ: ME) disclosed a data breach from December 2023 affecting 7 million users. Hackers targeted the personal genetic information of Jewish and Chinese customers, which was sold on the dark web. The breach was not fully disclosed to the affected customers, sparking a class action lawsuit. Hackers leaked 1 million Jewish profiles and 350,000 Chinese profiles in retaliation for global events and specific requests. The breach potentially endangers the safety of these individuals. 23andMe initially blamed recycled login credentials for the breach and delayed full disclosure until December.
On June 11, 2024, 23andMe (NASDAQ:ME) revealed a December 2023 data breach that compromised the personal information of 7 million users. Hackers specifically targeted the genetic data of Jewish and Chinese customers, hiding these details from the public. The breach led to a class action lawsuit, alleging that 23andMe failed to inform affected users. The hackers sold the stolen data on the dark web, posing significant safety risks, especially for Chinese citizens. The company blamed recycled login credentials for the breach and delayed its full disclosure until December 2023.
23andMe (NASDAQ:ME) experienced a data breach in December 2023, impacting around 7 million users. Hackers targeted the genetic information of Jewish and Chinese customers, selling it on the dark web. Despite knowing the specifics, 23andMe did not inform affected customers about their personal data being compromised. This resulted in significant safety concerns, especially for Jewish and Chinese users. A class-action lawsuit has been filed against the company, accusing it of negligence and failing to protect user data. The law firm Levi & Korsinsky is investigating potential compensation for affected users.